For research use only. Not for therapeutic Use.
CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI). CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases[1]. CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
| Catalog Number | I042647 |
| CAS Number | 1030595-07-3 |
| Synonyms | (2R,4R,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-4-fluoro-2-(hydroxymethyl)oxolan-3-ol |
| Molecular Formula | C12H11F2N5O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C12H11F2N5O3/c1-2-12(3-20)7(21)5(13)10(22-12)19-4-16-6-8(15)17-11(14)18-9(6)19/h1,4-5,7,10,20-21H,3H2,(H2,15,17,18)/t5-,7?,10-,12-/m1/s1 |
| InChIKey | CKOSILJGTGQALV-IVOINJCQSA-N |
| SMILES | C#CC1(C(C(C(O1)N2C=NC3=C(N=C(N=C32)F)N)F)O)CO |
| Reference | [1]. Hou J, et al. 4′-Ethynyl-2′-deoxy-2′-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection. J Med Chem. 2023 Aug 24;66(16):11282-11293. |
